Form 4: Kymera Therapeutics Executive Trades Common Stock

Noah Goodman, Chief Business Officer at Kymera Therapeutics, Inc., reported transactions involving common stock, including purchases made under a Rule 10b5-1 trading plan.

Summary

• Noah Goodman, Chief Business Officer of Kymera Therapeutics, Inc. (KYMR), reported transactions on July 1, 2026.
• Goodman acquired 3,389 shares of common stock at a price of $114.29 per share.
• These transactions were executed under a Rule 10b5-1 trading plan established on December 10, 2025.
• Following these transactions, Goodman beneficially owns 47,179.438 shares of common stock.
• The filing also notes that 373 shares were acquired under the company's employee stock purchase plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions under a pre-defined plan, providing no new fundamental information about the company's performance or prospects.

Positives

• Executive demonstrates continued investment in the company through stock acquisition.
• Transactions were conducted under a pre-established Rule 10b5-1 plan, indicating planned and orderly trading activity.
• Acquisition of shares at $114.29 per share suggests a belief in the company's valuation at that price point.

Negatives

• No explicit negative information is present in this Form 4 filing.

Risks

• The Rule 10b5-1 plan itself is subject to market fluctuations and the underlying performance of Kymera Therapeutics, Inc.
• Potential for future stock price declines could impact the value of the acquired shares.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The use of a Rule 10b5-1 plan by Noah Goodman at Kymera Therapeutics is a common practice for executives to manage their stock holdings in a way that avoids the appearance of insider trading, especially in the biopharmaceutical sector where stock prices can be volatile due to clinical trial results and regulatory approvals.

Stakeholder Impact

• Shareholders: The transaction itself does not directly impact shareholders, but it indicates executive confidence at the time of the trade. Future stock performance will affect all shareholders.
• Employees: The mention of the employee stock purchase plan suggests ongoing employee participation in company ownership.
• Management: Demonstrates adherence to disclosure requirements and use of established trading plans.

Next Steps

• Monitor future Form 4 filings for any additional transactions by Noah Goodman or other executives.
• Observe the ongoing performance of Kymera Therapeutics, Inc. to assess the long-term value of the acquired shares.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Trading, Stock Transaction, Rule 10b5-1, Noah Goodman, Chief Business Officer, Common Stock, Beneficial Ownership